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Brief Definit ive Report
Innate lymphoid cells (ILCs) are important 
effectors in innate immunity, lymphoid tissue 
formation, and tissue homeostasis. ILCs are 
characterized by a lymphoid morphology and 
the absence of markers for T, B, or myeloid 
cells and express the IL-7 receptor (IL-7R; 
CD127; Spits et al., 2013; Yagi et al., 2014). 
ILCs can be divided into ILC1s, ILC2s, and 
ILC3s based on the effector cytokines produced 
and the key transcription factors that determine 
their development and functions (Spits et al., 
2013). For example, similar to Th2 cells, group 2 
ILCs (ILC2s) produce IL-5 and IL-13 and are 
found to mediate parasite expulsion, to contrib-
ute to regeneration of respiratory tissues after 
acute influenza virus infection, and to participate 
in airway inflammation and immune patholo-
gies (Moro et al., 2010; Neill et al., 2010; Price 
et al., 2010; Chang et al., 2011; Monticelli et al., 
2011). All known subsets of ILCs depend on 
ID2 and cytokine receptor common  chain 
for their development (Cao et al., 1995; Yokota 
et al., 1999; Moro et al., 2010). Transcription 
factors Rora, Gata3, Tcf1, Nfil3, and Gfi1 have 
been recently demonstrated to control ILC2 de-
velopment (Kashiwada et al., 2011; Halim et al., 
2012b; Hoyler et al., 2012; Mjösberg et al., 
2012; Wong et al., 2012; Klein Wolterink 
et al., 2013; Spooner et al., 2013; Yang et al., 
2013; Geiger et al., 2014; Seillet et al., 2014), 
and most of them have important roles in T cell 
development. ILCs are developed from com-
mon lymphoid progenitors (CLPs) and early 
ILC progenitors (ILCPs; Spits et al., 2013). 
However, it remains unclear how early pro-
genitors become committed to each ILC subset 
and which transcription factors are involved in 
this process.
Transcription factor Bcl11b (B cell leukemia/ 
lymphoma 11b) is required for the early T cell pro-
genitors to become committed to the T cell lin-
eage. Inactivation of the Bcl11b gene in the mouse 
causes failure of T cell lineage commitment and 
CORRESPONDENCE  
Pentao Liu:  
pl2@sanger.ac.uk
Abbreviations used: ChILP, 
common helper innate  
lymphoid progenitor; CLP, 
common lymphoid progenitor; 
IEL, intraepithelial lymphocyte; 
ILC, innate lymphoid cell; 
ILCP, ILC progenitor; LPL, 
lamina propria lymphocyte; 
LSK, LinSca1+c-Kit+; LTi, 
lymphoid tissue inducer; MLN, 
mesenteric LN; qRT-PCR, 
quantitative RT-PCR; siLP, 
small intestine lamina propria; 
Tam, Tamoxifen.
The transcription factor Bcl11b is specifically 
expressed in group 2 innate lymphoid cells 
and is essential for their development
Yong Yu,1 Cui Wang,1,2 Simon Clare,1 Juexuan Wang,1 Song-Choon Lee,1 
Cordelia Brandt,1 Shannon Burke,1 Liming Lu,1,4 Daqian He,2  
Nancy A. Jenkins,3 Neal G. Copeland,3 Gordon Dougan,1 and Pentao Liu1
1Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1HH, England, UK
2Institute of Animal Husbandry and Veterinary Science, Shanghai Academy of Agricultural Sciences, Shanghai 201106, China
3The Methodist Hospital Research Institute, Houston, TX 77030
4Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
Group 2 innate lymphoid cells (ILCs), or ILC2s, are a subset of recently identified ILCs, 
which play important roles in innate immunity by producing type 2 effector cytokines. 
Several transcription factors have been found to have critical functions in the  
development of both ILC2s and T cells. We report here that Bcl11b, a transcription factor 
essential in T cell lineage commitment and maintenance, is specifically expressed in pro-
genitors committed to the ILC2 lineage and is required for ILC2 development. The Bcl11b 
gene is expressed in 28% of ILC progenitors (ILCPs; common helper innate lymphoid 
progenitors or ILCPs expressing either ID2 or promyelocytic leukemia zinc finger, respec-
tively). Both in vitro and in vivo, these Bcl11b-expressing early ILCPs generate only ILC2s. 
Inactivation of Bcl11b causes a complete loss of ILC2 development from hematopoietic 
progenitors, which is confirmed upon immune challenge with either papain administration 
or influenza virus infection.
© 2015 Yu et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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RESULTS AND DISCUSSION
Bcl11b is specifically expressed in ILC2s
We previously reported that Bcl11b is expressed in all T cells, 
from DN2 thymocytes to mature T cells, using the Bcl11b-
Tdtomato reporter mouse (Bcl11bTd/Td; Li et al., 2010b). The 
Bcl11b gene expression was recently detected in ILC2 in 
RT-PCR (Wong et al., 2012; Yang et al., 2013). We took 
advantage of the Bcl11bTd/Td reporter mouse and further 
loss of the T cell identity (Wakabayashi et al., 2003; Ikawa 
et al., 2010; Li et al., 2010a,b; Avram and Califano, 2014). 
Two studies indicate that Bcl11b expression was detected 
in ILC2s (Wong et al., 2012; Yang et al., 2013). We thus 
systematically investigated Bcl11b gene expression in ILCs 
in a Bcl11b reporter mouse and identified the essential role 
of Bcl11b in the development of ILC2s from hematopoi-
etic progenitors.
Figure 1. The Bcl11b gene is specifically expressed  
in ILC2s in ILCs. (A) Flow cytometry was performed on ILC 
subsets to assess Bcl11b expression in the Bcl11bTd/Td mouse. BM 
and lung ILC2s were identified as LinIL-7R+IL-33R+CD25+; MLN  
ILC2s as LinIL-7R+Sca1+; LPL ILC2s as LinIL-7R+/lowKLRG1+; 
IEL ILC1s as LinNKp46+NK1.1+CD160+; liver DX5 and 
DX5+ NK cells as CD3TCRNK1.1+; LPL NCR+ ILC3s as 
LinNKp46+NK1.1; LPL CD4+ LTi cells as LinKLRG1IL-
7R+CD4+CCR6+; LPL CD4LTi cells as LinKLRG1IL-
7R+CD4CCR6+; and Lin as B220, CD19, CD5, CD3, CD8, 
TCR, TCR, CD11b, Gr-1, and Ter119. (B) Bcl11b-expressing 
leukocytes in the lung were elicited by IL-25 or IL-33 cytokine 
administration and examined by flow cytometry. Wild-type mice 
treated with PBS (wt+PBS) were used as the negative control for 
the Tdtomato signal. (C) Production of IL-5 (intracellular stain-
ing) by Bcl11b+ cells from ex vivo stimulated BM and lung cells 
was assessed by flow cytometry. Numbers in plots denote per-
centages of cells in the indicated areas. ILC gating strategies are 
noted in Fig. S1. Data in all panels are representative of three to 
nine mice analyzed in at least three independent experiments.
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A–C and G). In contrast, ILC1s and ILC3s, including in-
traepithelial lymphocyte (IEL) ILC1s, liver DX5+ and DX5 
NK cells, spleen NK cells, lamina propria lymphocyte (LPL) 
NCR+ILC3s, LPL CD4+ or CD4 lymphoid tissue inducers 
systematically explored Bcl11b expression in ILC develop-
ment. At steady state, Bcl11b expression was found in all 
ILC2s in the BM, the lung, the mesenteric LN (MLN), and 
small intestine lamina propria (siLP; Fig. 1 A and Fig. S1, 
Figure 2. Bcl11b marks early committed IL-
C2Ps. (A–C) Analysis of expression of Bcl11b, Gata3, 
ICOS, and IL-33R in the indicated populations of 
Bcl11bTd/Td mice. Bcl11b expression in BM LSKs, CLPs 
(LinFlt3+IL-7R+), and ChILPs (A) and in ChILPs and 
ILC2Ps (B) was assessed by flow cytometry. Gating 
strategies are noted in Fig. S2. (C) Expression of 
Gata3, ICOS, and IL-33R in ChILPs and ILC2Ps was 
analyzed by flow cytometry. (D) The in vivo differen-
tiation potential of Bcl11b+ChILPs, ILC2Ps, CLPs, and 
Bcl11bChILPs was assessed by adaptive transfer 
followed by flow cytometric analysis. Donor-derived 
cells (CD45.1) in the siLP were screened for ILC1, 
ILC2, and ILC3. (E) The in vitro differentiation poten-
tial of Bcl11b+ChILPs was also assessed by flow 
cytometry. Sorted Bcl11b and Bcl11b+ ChILPs were 
cultured on OP9 cells for 6 d in the presence of  
20 ng/ml IL-7 and 20 ng/ml SCF. ILC2 was defined  
as ICOShiNK1.1CD25+, ILC1/conventional NK was 
defined as ICOSlowNK1.1NKp46+, and ILC3 was 
defined as ICOSintNK1.1 as previously reported 
(Constantinides et al., 2014). Numbers in flow  
cytometry plots denote percentages of cells in the 
indicated areas. At least three mice were analyzed  
in each experiment, and all the experiments were 
independently repeated at least three times.
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of cells in the ChILP or ILCP compartment were reported 
to generate only ILC2s in vitro (Constantinides et al., 2014; 
Klose et al., 2014). High levels of Bcl11b expression mark 
the commitment of the T cell lineage in the thymus (Li et al., 
2010a,b; Yu et al., 2012). We asked whether Bcl11b is also 
involved in early development of ILC2s. Consistent with pre-
vious studies, Bcl11b expression was not detected in either 
the LinSca1+c-Kit+ (LSK) compartment or CLP (Fig. 2 A; 
Li et al., 2010b). However, in the ChILP compartment 
defined by LinFlt3IL-7R+47+CD27+CD25CD244+ 
(Fig. S2), coincidentally, Bcl11b expression was found in 28% 
of ChILPs (Fig. 2 A). Expression of Bcl11b appeared to in-
crease from Bcl11b+ChILPs to ILC2 progenitors (ILC2Ps; 
Fig. 2 B and Fig. S2). Moreover, Bcl11b+ChILPs expressed 
other ILC2 genes such as Gata3 and ICOS, but little IL-
33R (Fig. 2 C). To test whether these Bcl11b-expressing 
ChILPs overlap with those ones that generate only ILC2s 
(Constantinides et al., 2014; Klose et al., 2014), we intrave-
nously injected purified Bcl11b+ChILPs into sublethally ir-
radiated alymphoid Rag2/Il2rg/ mice to examine their 
in vivo developmental potential. 6–8 wk after transplantation, 
siLP cells from recipients were harvested for ILC analysis. 
Bcl11b+ChILPs produced only ILC2s, similar to what IL-
C2Ps (LinFlt3IL-7R+47+CD27+CD25+CD244) did 
(Fig. 2 D; Hoyler et al., 2012; Klose et al., 2014). On the 
other hand, both CLPs and Bcl11bChILPs produced CD4+ 
and CD4 LTi cells besides ILC2s (Fig. 2 D). These results 
indicate that these Bcl11b+ChILPs are already committed to the 
ILC2 lineage and may represent an earlier progenitor popu-
lation (CD25IL-33R) than ILC2P (CD25+IL-33R+). We 
subsequently performed short-term in vitro fate assay, which 
again demonstrated that Bcl11b+ChILPs only produced ILC2 
(Fig. 2 E). Therefore, Bcl11b expression in ChILPs marks 
early committed ILC2Ps.
Bcl11b has critical and cell-autonomous  
functions in early ILC2 development
We started investigating Bcl11b functions in ILC2 develop-
ment by examining the Bcl11b heterozygous germline loss of 
function mutant mice (+/) because the homozygous mu-
tants die at birth (Wakabayashi et al., 2003). Compared with 
the wild-type control mice (+/+), the heterozygotes had 
59% of ILC2s (LinIL-33R+IL-7R+CD25+) in the BM 
(Fig. 3 A and Fig. S3 A), indicating that Bcl11b has a dose-
dependent role in ILC2 development. Surprisingly, com-
pared with the wild-type control mice, the heterozygotes had 
significantly higher percentages of mature ILC2s in the BM 
defined by CD25+KLRG1+ (Fig. 3 B and Fig. S3 A), indicat-
ing that Bcl11b might also normally prevent production of 
mature ILC2s from progenitors. On the other hand, ILC2 
numbers in the lung of the heterozygotes were not signifi-
cantly reduced (Fig. 3 C and Fig. S3 B).
We performed further analysis of Bcl11b in ILC2 devel-
opment using the Bcl11bflox/floxRosa26CreERT2/CreERT2 conditional 
knockout mice (Li et al., 2010b). These mice were grossly 
normal and fertile as previously reported (Li et al., 2010b). 
(LTi’s), or LPL NKp46+NK1.1+ cells (including conventional 
NK cells, ILC1s, and ILC3s; Klose et al., 2014), did not have 
detectable Bcl11b expression (Fig. 1 A and Fig. S1, D–G).
We next examined Bcl11b expression in ILC2s in the pres-
ence of IL-25 and IL-33, as recent studies suggest that ILC2s 
are elicited by these cytokines (for example, Neill et al., 2010). 
To minimize the background of the adaptive immune re-
sponses and to eliminate potential contamination with T cells, 
we crossed Bcl11bTd/Td reporter mouse to the Rag1/ knock-
out mouse to obtain Bcl11bTd/TdRag1/ mice. In Bcl11bTd/
TdRag1/ mice, 0.85% of the lung leukocytes expressed 
Bcl11b, and 20% of them expressed the mature ILC2 marker 
KLRG1 (Fig. 1 B; Hoyler et al., 2012). Once IL-25 or IL-33 
was administered, Bcl11b-expressing lung leukocytes increased 
to 34% and 36%, respectively (Fig. 1 B). Notably, almost all of 
the expanded cells expressed KLRG1 (Fig. 1 B).
Similar to Th2 cells, ILC2s secrete type 2 cytokines such 
as IL-5 and IL-13 (Spits et al., 2013). We next purified 
LinBcl11b+ leukocytes from the BM and the lung of 
Bcl11bTd/TdRag1/ mice and briefly stimulated these cells 
ex vivo with PMA and Ionomycin for IL-5 production (Hoyler 
et al., 2012). Many LinBcl11b+ cells produced IL-5 (Fig. 1 C). 
In contrast, the LinBcl11b cells from both the BM and the 
lung did not have detectable IL-5 production (Fig. 1 C). These 
results thus demonstrate that Bcl11b is specifically expressed 
in ILC2s in ILCs.
Recent studies indicate that ILCs are differentiated from 
progenitors, which, in turn, originate from CLPs in the BM 
(Spits et al., 2013; Constantinides et al., 2014; Klose et al., 
2014). Analysis of reporter mouse lines has identified two 
overlapping ILCP populations: common helper innate lym-
phoid progenitor (ChILP) cells that express ID2 (Klose et al., 
2014) and ILCPs, which are characterized by the expres-
sion of promyelocytic leukemia zinc finger (Constantinides 
et al., 2014). Both progenitor populations can give rise to 
three types of ILCs but are heterogeneous as revealed in 
in vitro single-cell developmental fate assays. Notably, 28% 
Figure 3. Bcl11b has a dose-dependent role in ILC2 development. 
ILC2s in the adult (14 wk old) wild-type mice (+/+) and Bcl11b mutant 
heterozygotes (+/) were analyzed by flow cytometry and quantitated. 
(A) Cell numbers of ILC2s (LinIL-7R+IL-33R+CD25+) in the BM. (B) Per-
centages of KLRG1+ cells in BM ILC2s. (C) Lung ILC2s (LinIL-7R+IL-
33R+CD25+). Error bars indicate the SD. In all panels, n = 4 mice per 
genotype were analyzed, and each experiment was independently repeated 
at least three times. Statistical significance is indicated as follows: *, P < 
0.05; **, P < 0.01. ns, not significant. Gating strategies are noted in Fig. S3.
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or Bcl11b+/+Rosa26CreERT2/CreERT2 BM cells into lethally irradi-
ated CD45.1+ C57B6 recipients. The recipients were allowed 
6–8 wk for donor cell reconstitution before Tam was admin-
istered to delete Bcl11b. BM cells from these mice were sub-
sequently harvested 3–4 wk after Tam treatment. Again, only 
6% of donor ILC2s was left in the BM after Bcl11b deletion 
(Fig. 4 E and Fig. S4 B). In contrast, no obvious changes were 
found in BM ILC1Ps (LinNK1.1+NKp46+IL7R+CD49a+; 
Fig. 4 F and Fig. S4 C; Klose et al., 2014).
We next purified BM hematopoietic progenitors (LSKs) 
from either Tam-treated Bcl11bflox/floxRosa26CreERT2/CreERT2 
(Bcl11bfl/fl) or control mice and intravenously injected these 
cells into lethally irradiated alymphoid Rag2/Il2rg/ re-
cipients (CD45.1+; Serafini et al., 2014) with helper BM cells 
(CD45.1+). After 8 wk of engraftment, the recipients were 
analyzed for ILC engraftment. Control LSKs (Bcl11b+/+) ef-
ficiently generated ILC2s in the BM, the lung, and the siLP, 
as well as ILC1Ps in the BM (Fig. 4, G–K, and Fig. S5, A–C). 
Bcl11b deletion in these mice was achieved by administration 
of Tamoxifen (Tam; the treated mice are referred to as Bcl11bfl/fl). 
We chose Bcl11b+/+Rosa26CreERT2/CreERT2 mice as the control 
(the treated mice are referred to as Bcl11b+/+) to help exclude 
the potential defects from Cre toxicity. We analyzed the mice 
2–3 wk after Tam administration. Bcl11b deletion caused se-
vere phenotypes in the BM ILC2 compartment, with only 
6% left compared with the control (Fig. 4, A and B). In 
contrast, lung ILC2s were not obviously reduced (Fig. 4 C 
and Fig. S4 A). Rather, more of them expressed KLRG1 
(Fig. 4 D and Fig. S4 A), which is consistent with the result 
that the Bcl11b heterozygous mutants have increased mature 
ILC2s (Fig. 3 B and Fig. S3 A). This result shows that Bcl11b 
inactivation causes severe defects in early development of 
ILC2s in the BM.
To address whether the defects in ILC2s caused by Bcl11b 
deficiency were cell autonomous or intrinsic to hematopoietic 
cells, we intravenously injected Bcl11bflox/floxRosa26CreERT2/CreERT2 
Figure 4. Bcl11b has critical and cell-autonomous functions in early ILC2 development. (A–D) ILC2s in BM (A and B) and lung (C and D) of 
Bcl11bfl/fl or control mice were analyzed by flow cytometry. (A) BM ILC2s were detected by either LinIL-7R+IL-33R+ or LinIL-33R+CD25+. (B) BM ILC2 
numbers in Bcl11bfl/fl or control mice were analyzed as shown. (C and D) The numbers of lung ILC2s and KLRG1+ILC2s in the Bcl11bfl/fl or the control mice 
were enumerated as shown. (E and F) Donor-derived BM ILC2s and ILC1Ps in chimeras engrafted with Bcl11bfl/fl BM cells 3–4 wk after Tam treatment. 
(G–K) LSKs from the Bcl11bfl/fl or control mice were transplanted into the Rag2/Il2rg/ recipients (CD45.1+). 8 wk after engraftment, the donor cells 
(CD45.1) were analyzed by flow cytometry. (G) Donor LSK-derived ILC2s in the BM were analyzed by flow cytometry. (H–J) ILC2s or ILC1s were enumer-
ated as shown. (H) BM ILC2 numbers. (I) BM ILC1P numbers. (J) Lung ILC2 numbers. (K) siLP ILC2 numbers. Error bars indicate the SD. Numbers in flow 
cytometry plots denote percentages of cells in the indicated areas. All the experiments were independently repeated at least three times. n = 4 mice per 
genotype. Statistical significance is indicated as follows: *, P < 0.05; **, P < 0.01. Additional gating strategies are noted in Figs. S4 and S5.
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In contrast, Bcl11bfl/fl LSKs generated no ILC2s in the BM of 
chimeras (Fig. 4, G and H), and there were barely any detectable 
ILC2s in the lung or in the siLP (Fig. 4, J and K, and Fig. S5, 
B and C). On the other hand, ILC1Ps in the BM or LPL 
CD4+ or CD4 LTi cells were not affected by Bcl11b dele-
tion (Fig. 4 I and Fig. S5, A and C).
Bcl11b deletion promotes expression of genes  
that are at high levels in mature ILC2s
It was reported that the OP9-DL1 culture system allows 
CLPs to differentiate to ILC2s (Wong et al., 2012). We puri-
fied Bcl11bfl/fl CLPs and co-cultured them with OP9-DL1 
stromal cells. No ILC2s were produced from Bcl11bfl/fl CLPs 
(Fig. 5 A), which is consistent with the previous in vivo data. 
Our previous study demonstrates that Bcl11b is essential for 
T cell identity maintenance (Li et al., 2010b). To investigate 
the functions of Bcl11b in the committed ILC2s and to test 
whether Bcl11b is also required for ILC2 identity maintenance, 
we purified ILC2Ps from Bcl11bflox/floxRosa26CreERT2/CreERT2 
conditional knockout mice and cultured them on OP9-DL1 
stromal cells to produce ILC2s. We subsequently treated the 
cultured cells with Tam to delete Bcl11b. After IL-25 or 
IL-33 stimulation, Bcl11bfl/fl ILC2s were still able to produce 
IL-5 but not IFN- (Fig. 5 B), demonstrating that commit-
ted ILC2s are able to produce type 2 cytokine in the absence 
of Bcl11b, in contrast to its essential role in the early develop-
ment of ILC2s. However, deletion of Bcl11b led to substan-
tially more ILC2s that expressed KLRG1 (Fig. 5 C), which 
is consistent with the in vivo data (Fig. 3 B, Fig. 4 D, Fig. S3 A, 
and Fig. S4 A). Moreover, Bcl11b deficiency led to higher 
percentages of ILC2s producing IL-5 (Fig. 5 B). Therefore, 
Bcl11b is essential for the differentiation of ILC2s from 
hematopoietic progenitors but may also suppress genes that 
are highly expressed in mature ILC2s. Indeed, quantitative 
RT-PCR (qRT-PCR) confirmed up-regulation of Il5, Il13, 
Klrg1, Gata3, and Rora, which are highly expressed in ma-
ture ILC2s (Hoyler et al., 2012) in Bcl11bfl/fl ILC2 cultures 
(Fig. 5 D).
Immune challenges confirm no functional ILC2s generated 
from Bcl11b-deficient hematopoietic progenitors
Recent studies suggest a critical role for ILC2s in mediating 
protease-induced airway inflammation (for example, Halim 
et al., 2012a). We wished to confirm the essential role of Bcl11b 
in ILC2 development upon immune challenges. We puri-
fied LSKs from Bcl11bflox/floxRosa26CreERT2/CreERT2Rag1/ mice 
Figure 5. Bcl11b is required for ILC2 development from early  
progenitors in vitro but represses genes that are highly expressed  
in mature ILC2s. (A) In vitro differentiation potential of CLPs to ILC2s 
(ICOS+IL-33R+) was assessed by flow cytometry. Bcl11bfl/fl and control 
CLPs were cultured on OP9-DL1 cells in the presence of IL-7 and IL-33 for 
22 d before flow cytometric analysis. In each experiment, CLPs from three 
to four mice of each genotype were pooled. (B and C) Purified BM ILC2s 
(LinFlt3IL-7R+47+CD27+CD25+CD244) were cultured on OP9-DL1 
cells in the indicated conditions, and expression of IL-5 and KLRG1 in 
these cells was assessed by flow cytometry 10–14 d after Tam treatment. 
(D) Expression of Bcl11b, Rora, Il5, Il13, Klrg1, and Gata3 in cultured 
Bcl11bfl/fl ILC2s was assessed by qRT-PCR. Data represent mean values of 
three independent biological replicates, and all values were normalized to 
Gapdh expression. Expression of genes in the control cells was normalized 
as one. Error bars indicate the SD. Numbers in flow cytometry plots  
denote percentages of cells in the indicated areas. All the experiments 
were independently repeated at least three times. Statistical significance 
is indicated as follows: **, P < 0.01.
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the bronchoalveolar lavage (BAL) fluid and in the lung in 
control recipients, but not in the Bcl11bfl/flRag1/ ones (Fig. 6, 
C and D). Furthermore, the papain challenge also failed to 
induce IL-5 or IL-13 production in the BAL fluid in the re-
cipients from Bcl11bfl/flRag1/ LSKs (Fig. 6 E).
Influenza virus infection induces type 2 immune responses 
and production of prototypical cytokines such as IL-5 by 
ILC2s (Gorski et al., 2013), which is linked to asthma exacer-
bation. We thus examined immune responses of BM chimeras 
that were treated with Tam (Bcl11bfl/flRag1/) and transplanted 
them to sublethally irradiated alymphoid Rag2/Il2rg/ 
recipients (CD45.1+). 8–10 wk after engraftment, the recipi-
ents were intranasally challenged with papain, which induces 
rapid IL-5 production and eosinophil infiltration in the air-
way (Halim et al., 2012a). Consistent with our above results 
(Fig. 4 J and Fig. S5 B), no ILC2s were elicited in the lung 
after papain challenge in Bcl11bfl/flRag1/ chimeras at 84 h 
(Fig. 6, A and B). Papain induced eosinophil infiltration in 
Figure 6. Immune challenges confirm no ILC2 development from Bcl11b-deficient hematopoietic progenitors. LSKs of Bcl11bfl/flRag1/ or the 
control (Bcl11b+/+Rag1/) were transplanted into Rag2/Il2rg/ mice recipients (CD45.1+) and subjected to papain treatment (intranasally) or influ-
enza virus infection (inoculated intranasally). (A–E) ILC2-mediated lung immune responses after papain treatment were assessed by flow cytometry. 
(A and B) Donor ILC2s (CD45.1LinIL-7R+IL-33R+CD25+) in the lung were analyzed by flow cytometry and enumerated as shown. (C and D) Eosinophil 
(Siglec-F+CD11c) infiltration in the lung and BAL of mouse recipients was enumerated as shown. (E) IL-5 and IL-13 production in the BAL fluid of recipi-
ent mice was assessed by flow cytometry. (F) Lung ILC2s or BAL fluid IL-5 in recipients after influenza virus infection (H3N2) or allantoic fluid diluted 
1:500 in PBS as the mock was assessed by flow cytometry and was quantitated as shown. (A and C) Numbers in the flow cytometry plots denote percent-
ages of cells in the indicated areas. (A–F) Error bars indicate the SD. All the experiments were independently repeated at least three times (n = 4 mice per 
genotype). Statistical significance is indicated as follows: **, P < 0.01. Additional gating strategies are noted in Fig. S6.
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NK1.1 (PK136), Nkp46 (29A1.4), CD11b (M1/70), CD11c (N418), Gr1 
(RB6-8C5), Ter119 (TER-119), c-kit (2B8), Flt3 (A2F10), Sca1 (D7), IL-
7R (SB/199), CD25 (PC61), CD45.1 (A20), CD45 (30-F11), Siglec-F 
(E50-2440), CD27 (LG.3A10), CD244 (2B4), 47 (DATK32), IL-33R 
(RWST2-2), CCR6 (29-2L 17), IL-5 (TRFK5), IL-13 (eBio13a), IFN- 
(XMG1.2), Gata3 (L50-823), and RORt (Q31-378) were purchased from 
BD, BioLegend, or eBioscience. LEGENDplex Mouse Th2 Panel (6-plex) 
(BioLegend) was used for BAL cytokine detection.
Flow cytometry and cell sorting. RBCs were removed using ACK 
(Ammonium-Chloride-Potassium) Lysing Buffer (Lonza). Cells were suspended 
in a solution of 2% (vol/vol) FBS in PBS. Fc receptors were blocked with 
anti-CD16 (2.4G2) before antibody labeling. Cells were stained with antibod-
ies on ice for 20 min before washing. Intracellular staining was performed ac-
cording to the instructions of the FOXP3 Fix/Perm Buffer Set (BioLegend). 
Cells were analyzed on a Fortessa (BD) or sorted on a MoFlo XDP (Beckman 
Coulter) according to the manufacturers’ standard operating procedures. Data 
were analyzed with FlowJo software, version X.0.7 (Tree Star).
Preparation of cell suspensions. BM cells were isolated by gently crushing 
femurs and tibias before filtration (70-µm filter). Cells from lung and siLP were 
prepared according to the instructions of the Lung Dissociation kit (Miltenyi 
Biotec) and Lamina Propria Dissociation kit (Miltenyi Biotec), respectively. 
The tissues were digested in a shaking water bath at 37°C for 30 min. After 
dissociation, leukocytes were enriched by percoll gradient centrifugation.
Ex vivo production of cytokines from ILC2 cells. ILC2s were stimu-
lated ex vivo with PMA and Ionomycin (Cell Stimulation Cocktail; eBiosci-
ence) for 4 h for IL-5 production, in the presence of the protein transport 
inhibitor cocktail (eBioscience). The cells were subsequently stained intra-
cellularly for IL-5.
Cytokine administration in vivo. Mice were given intraperitoneal injec-
tions of 500 ng IL-25 or IL-33 (BioLegend) on days 0–3. On day 4, tissues 
were collected for analysis.
Adoptive transfers in vivo. For adoptive transfer experiments, cell popu-
lations highly purified by flow cytometry were injected intravenously into 
sublethally irradiated (1 × 450 rad) Rag2/Il2rg/ recipient mice (CD45.1+) 
via the tail vein. The drinking water was supplemented with antibiotics for 
2 wk after irradiation.
BM chimeras. Single-cell suspensions of BM cells from the Bcl11bflox/flox 
Rosa26CreERT2/CreERT2 and control Bcl11b+/+Rosa26CreERT2/CreERT2 mice were 
injected intravenously into lethally irradiated (2 × 500 rad) C57B6 recipient 
mice (CD45.1+) for reconstitution for 6–8 wk. The drinking water was sup-
plemented with antibiotics for 2 wk after irradiation.
For hematopoietic progenitor reconstitution in vivo, the LSKs were pu-
rified from the BM of Bcl11bfl/fl, Bcl11bfl/flRag1/, or the Bcl11b+/+ or 
Bcl11b+/+Rag1/ control mice. The sorted LSKs (10,000 cells) were injected 
into sublethally irradiated (1 × 450 rad) Rag2/Il2rg/ recipient mice 
(CD45.1+) or with helper CD45.1+ BM cells (2 × 105 cells) into lethally irradi-
ated (2 × 500 rad) Rag2/Il2rg/ recipient mice (CD45.1+) via the tail vein.
Papain administration. The mice were anesthetized with 3% isoflurane 
and then were intranasally administered with papain (10 µg in 40 µl PBS) 
every 24 h on days 0–2. 12 h after the last challenge, lungs and BAL fluid 
were collected and analyzed.
Influenza virus infection. The BM chimeras were anesthetized with 3% 
isoflurane and were inoculated intranasally with influenza A virus X31 (H3N2) 
in 50 µl PBS of 104 PFU. The virus was grown and collected from embryo-
nated chicken eggs (48–72 h). The control (mock infected) mice were treated 
intranasally with allantoic fluid diluted 1:500 in PBS. On day 5 after infection, 
lung and BAL fluid (lavaged with 0.4 ml PBS) were collected.
reconstituted with LSKs upon influenza virus infection. In-
fluenza virus infection induced expansion of ILC2s in the 
lung of the control recipient chimeras at day 5 after infection 
(Fig. 6 F and Fig. S6). In contrast, chimeras of Bcl11bfl/flRag1/ 
LSKs completely lacked ILC2s in the lung (Fig. 6 F and Fig. S6). 
The control recipients, but not Bcl11bfl/flRag1/ LSK chime-
ras, produced abundant IL-5 in the BAL fluid after influenza 
virus infection (Fig. 6 F). In summary, both immune chal-
lenges confirm the complete lack of ILC2 development po-
tential in the Bcl11b-deficient hematopoietic progenitors.
We report here that Bcl11b is specifically expressed in 
ILCPs that are committed to ILC2s and is essential for ILC2 
development. Several transcription factors have been shown to 
have important functions in ILC2 development. Gata3 is criti-
cal for controlling the cell fate of ILC2s (Hoyler et al., 2012; 
Mjösberg et al., 2012; Klein Wolterink et al., 2013) and also 
for all IL-7R–expressing ILC development (Yagi et al., 
2014). Rora appears to be specifically required for inducing 
ILC2s (Halim et al., 2012b; Wong et al., 2012), but not 
RORt-expressing ILCs (Halim et al., 2012b). However, 
Rora is also expressed in other ILC subsets (see microarray data 
in Hoyler et al., 2012). Nfil3 is shown to control type 2 Th 
cytokine expression (Kashiwada et al., 2011), but recent results 
demonstrate that it is a key regulator of the development of 
other ILC subsets essential for immune protection in the lung 
and gut (Geiger et al., 2014; Seillet et al., 2014). Bcl11b is dif-
ferent from these factors. It is the first transcription factor that 
is found specifically expressed in ILC2s and is required for de-
velopment of ILC2s from hematopoietic progenitors, a func-
tion similar to its role in T cell development. Interestingly, 
deletion of Bcl11b in ILC2s led to higher expression of many 
ILC2 genes, including several transcription factors mentioned 
above (Fig. 5 D). This is also reminiscent of Bcl11b’s role in 
T cells, where deleting Bcl11b results in up-regulated expres-
sion of genes of mature T cells (Kastner et al., 2010). Further 
dissection of the molecular and cellular mechanisms of Bcl11b 
in ILC2s and ILC-specific deletion of Bcl11b using the Cre 
system should facilitate better understanding of ILCs and of 
Bcl11b’s potential role in human disease.
MATERIALS AND METHODS
Mice. The Bcl11b-Tdtomato reporter mice (Bcl11bTd/Td) and Bcl11bflox/flox 
Rosa26CreERT2/CreERT2 mice were generated on the C57BL/6 genetic back-
ground by backcrossing to C57BL/6 mice for 11 generations. The Bcl11bflox/flox 
Rosa26CreERT2/CreERT2 mice were crossed to Rag1/ mice (C57BL/6) to gen-
erate Bcl11bflox/floxRosa26CreERT2/CreERT2Rag1/ mice. Bcl11b germline hetero-
zygous mutant (+/) and the wild-type control mice (+/+) were on the 
129S5 background. C57BL/6 CD45.1+ wild-type or Rag2/Il2rg/ mice 
(C57BL/6 CD45.1; Serafini et al., 2014) were used as recipients for trans-
plantation of BM cells or LSKs. All mice used were from colonies main-
tained at the research support facility of the Sanger Institute. Housing and 
breeding of mice and experimental procedures were done according to the 
UK 1986 Animals (Scientific Procedures) Act and the Animal Welfare and 
Ethical Review Body of the Wellcome Trust Sanger Institute.
Reagents. Fluorochrome- or biotin-labeled monoclonal antibodies (clones 
denoted in parentheses) against B220 (RA3-6B2), CD19 (6D5), CD3 
(145-2C11), CD8 (53–6.7), TCR (B20.6), CD49b (DX5), TCR (GL3), 
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In vitro culture assays. The ILC2 differentiation potential of hematopoi-
etic progenitors was performed as previously reported (Wong et al., 2012). 
In brief, freshly sorted CLPs from the Bcl11bflox/floxRosa26CreERT2/CreERT2 and 
control Bcl11b+/+ Rosa26CreERT2/CreERT2 mice that were treated with Tam 4 d 
earlier (4.0 mg Tam by intraperitoneal injection over three consecutive days) 
were cultured on OP9-DL1 monolayers in the presence of 10 ng/ml IL-7 
(PeproTech) and 10 ng/ml IL-33 (PeproTech) for 22 d.
For the short-term fate assay, purified Bcl11bChILPs and Bcl11b+ChILPs 
were cultured on OP9 monolayers in the presence of 25 ng/ml IL-7 (Pepro-
Tech) and 25 ng/ml Stem Cell Factor (SCF; PeproTech) for 6 d as previ-
ously described (Constantinides et al., 2014).
For deleting Bcl11b in ILC2s, sorted ILC2Ps from the BM of 
Bcl11bfloxfloxRosa26CreERT2/CreERT2 and control mice were cultured on OP9-DL1 
monolayers in the presence of 20 ng/ml IL-7, 20 ng/ml SCF, and 10 ng/ml 
IL-2 or 20 ng/ml IL-7 plus 20 ng/ml IL-25 or plus 20 ng/ml IL-33. After 
3–5 d, Tam was added in the medium to induce Bcl11b deletion in vitro. 
Cells were collected and analyzed 10–14 d after Tam treatment.
qRT-PCR. RNA was extracted from in vitro cultured ILC2 and reverse 
transcribed. TaqMan primer and probe sets (Applied Biosystems) were used 
for quantification of the expression of Bcl11b, Rora, Tcf7, Gata3, Il-5, Il-13, 
and Klrg1. Expression was quantified relative to that of Gapdh.
Statistical analysis. Data were statistically analyzed and figures were pre-
pared using Microsoft Excel. A two-tailed Student’s t test was used through-
out this work to evaluate statistical significance. Significance is indicated as 
follows: *, P < 0.05; **, P < 0.01.
Online supplemental material. Fig. S1 contains gating strategies of ILCs. 
Fig. S2 shows the gating strategies of ILCPs. Fig. S3 presents the gating 
strategies of ILC2s in the BM and lung of wild-type and Bcl11b het-
erozygous mutant mice. Fig. S4 contains gating strategies of ILCs in the 
Bcl11bflox/floxRosa26CreERT2/CreERT2 mice, control mice, or in BM chimeras. 
Fig. S5 shows gating strategies of donor LSK-derived ILCs in chimeras. Fig. S6 
presents gating strategies of ILC2s in the lung of recipients engrafted with 
the control or Bcl11bfl/flRag1/ LSKs after influenza virus (H3N2) infec-
tion. Online supplemental material is available at http://www.jem.org/cgi/ 
content/full/jem.20142318/DC1.
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